These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2891030)

  • 21. Psychostimulant properties of MDMA.
    Gold LH; Geyer MA; Koob GF
    NIDA Res Monogr; 1989; 95():345-6. PubMed ID: 2577038
    [No Abstract]   [Full Text] [Related]  

  • 22. MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens.
    Müller F; Holze F; Dolder P; Ley L; Vizeli P; Soltermann A; Liechti ME; Borgwardt S
    Neuropsychopharmacology; 2021 Feb; 46(3):545-553. PubMed ID: 33219313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular modeling of the interaction of LSD and other hallucinogens with 5-HT2 receptors.
    Westkaemper RB; Glennon RA
    NIDA Res Monogr; 1994; 146():263-83. PubMed ID: 8742803
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of MDMA ('ecstasy') on firing rates of serotonergic, dopaminergic, and noradrenergic neurons in the rat.
    Piercey MF; Lum JT; Palmer JR
    Brain Res; 1990 Sep; 526(2):203-6. PubMed ID: 1979517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex.
    Arvanov VL; Liang X; Russo A; Wang RY
    Eur J Neurosci; 1999 Sep; 11(9):3064-72. PubMed ID: 10510170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions.
    White FJ
    Pharmacol Biochem Behav; 1986 Feb; 24(2):365-79. PubMed ID: 3952127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis.
    Sadzot B; Baraban JM; Glennon RA; Lyon RA; Leonhardt S; Jan CR; Titeler M
    Psychopharmacology (Berl); 1989; 98(4):495-9. PubMed ID: 2505289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the behavioral and neurochemical effects of 5,7-DHT, MDMA and D,L-fenfluramine.
    Lorens SA; Hata N; Cabrera T; Hamilton ME
    NIDA Res Monogr; 1989; 95():347. PubMed ID: 2577039
    [No Abstract]   [Full Text] [Related]  

  • 29. Neurophysiological effects of hallucinogens on serotonergic neuronal systems.
    McCall RB
    Neurosci Biobehav Rev; 1982; 6(4):509-14. PubMed ID: 7177511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analyzing mechanism(s) of hallucinogenic drug action with drug discrimination procedures.
    Appel JB; White FJ; Holohean AM
    Neurosci Biobehav Rev; 1982; 6(4):529-36. PubMed ID: 7177512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurotransmitter basis of the behavioral effects of hallucinogens.
    Rech RH; Commissaris RL
    Neurosci Biobehav Rev; 1982; 6(4):521-7. PubMed ID: 6817241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 'Candyflipping': synergistic discriminative effect of LSD and MDMA.
    Schechter MD
    Eur J Pharmacol; 1998 Jan; 341(2-3):131-4. PubMed ID: 9543229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors.
    Gresch PJ; Strickland LV; Sanders-Bush E
    Neuroscience; 2002; 114(3):707-13. PubMed ID: 12220572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Actions of serotonin and related substances on single neurons in the brain.
    Bradley PB; Briggs I
    Adv Biochem Psychopharmacol; 1974; 10():159-66. PubMed ID: 4527120
    [No Abstract]   [Full Text] [Related]  

  • 35. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain.
    Nichols CD; Sanders-Bush E
    Neuropsychopharmacology; 2002 May; 26(5):634-42. PubMed ID: 11927188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration.
    Nichols CD; Garcia EE; Sanders-Bush E
    Brain Res Mol Brain Res; 2003 Mar; 111(1-2):182-8. PubMed ID: 12654518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2: Review of the Evidence.
    Hosanagar A; Cusimano J; Radhakrishnan R
    J Clin Psychiatry; 2021 Feb; 82(3):. PubMed ID: 33988930
    [No Abstract]   [Full Text] [Related]  

  • 38. Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain.
    Hungen KV; Roberts S; Hill DF
    Brain Res; 1975 Aug; 94(1):57-66. PubMed ID: 238721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mechanism of action of hallucinogenic drugs on a possible serotonin receptor in the brain.
    Smythies JR; Benington F; Morin RD
    Int Rev Neurobiol; 1970; 12():207-33. PubMed ID: 4918144
    [No Abstract]   [Full Text] [Related]  

  • 40. 'Hallucinogenic drugs and central transmitter substances'.
    Leonard BE
    Int J Neurosci; 1972 Jul; 4(1):35-43. PubMed ID: 4348844
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.